M&T Bank Corp Has $119.99 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

M&T Bank Corp decreased its position in Eli Lilly and Company (NYSE:LLY) by 5.2% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 205,838 shares of the company’s stock after selling 11,185 shares during the period. M&T Bank Corp’s holdings in Eli Lilly and Company were worth $119,987,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Lipe & Dalton bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $26,000. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $27,000. Legacy Financial Group LLC bought a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $35,000. Optiver Holding B.V. acquired a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $36,000. Finally, Family CFO Inc bought a new position in Eli Lilly and Company in the third quarter valued at approximately $40,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $20.94 during midday trading on Friday, reaching $734.97. The company’s stock had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. The company has a market cap of $698.52 billion, a P/E ratio of 108.24, a P/E/G ratio of 1.46 and a beta of 0.37. Eli Lilly and Company has a fifty-two week low of $419.80 and a fifty-two week high of $800.78. The company has a debt-to-equity ratio of 1.90, a quick ratio of 0.73 and a current ratio of 1.35. The business’s 50 day moving average price is $761.06 and its two-hundred day moving average price is $671.38.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the prior year, the company posted $1.62 EPS. The company’s revenue was up 26.0% compared to the same quarter last year. On average, analysts forecast that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Analyst Ratings Changes

LLY has been the topic of a number of research analyst reports. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Citigroup boosted their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Truist Financial increased their price objective on Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a report on Wednesday. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research report on Wednesday, February 21st. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.